Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
08:30am, Thursday, 14'th Aug 2025
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA
09:40am, Monday, 11'th Aug 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
09:00am, Monday, 11'th Aug 2025
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment
09:28am, Monday, 21'st Jul 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
07:00am, Monday, 21'st Jul 2025
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
11:08pm, Friday, 13'th Jun 2025
Tiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralu
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
11:03am, Friday, 13'th Jun 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences to Present at the Bio International Convention
08:30am, Friday, 13'th Jun 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease
07:00am, Friday, 23'rd May 2025
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
09:43am, Thursday, 15'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's diseas
Tiziana Life Sciences Announces Purchase of Shares by Chairman
07:00am, Monday, 12'th May 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
09:31am, Friday, 09'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead dr
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana shares surge 21% on promising multiple sclerosis data
10:57am, Tuesday, 06'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralu
